Source link : https://www.newshealth.biz/health-news/accelerated-approval-of-new-tki-use-in-cml-sparks-questions/
US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available for this condition. In October, the US Food and Drug Administration (FDA) granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with […]
Author : News Health
Publish date : 2024-12-02 11:21:22
Copyright for syndicated content belongs to the linked Source.